"Accessible Entrance for Drop Offs and Appointments The Farm Journal Building entrance at 230 West Washington Square includes stairs. For an accessible entrance to the building and valet parking, please use the entrance at 719 Manning Street."

During the past decade, Pennsylvania Oncology Hematology Associates conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 17 clinical trials were completed, i.e. on average, 1700% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 5 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pennsylvania Oncology Hematology Associates" #1 sponsor was "AIDS Malignancy Consortium" with 4 trials, followed by "Sarcoma Alliance for Research through Collaboration" with 4 trials sponsored, "Accelerated Community Oncology Research Network" with 3 trials sponsored, "Hoosier Cancer Research Network" with 3 trials sponsored and "Fox Chase Cancer Center" with 3 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pennsylvania Oncology Hematology Associates" #1 collaborator was "National Cancer Institute (NCI)" with 7 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator, "The Emmes Company, LLC" with 4 trials as a collaborator and "AstraZeneca" with 2 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Pennsylvania Oncology Hematology Associates" are "Colorectal Cancer" (4 trials), "Breast Cancer" (3 trials), "HIV Infections" (3 trials), "Lung Cancer" (3 trials) and "Lymphoma" (3 trials). Many other conditions were trialed in "Pennsylvania Oncology Hematology Associates" in a lesser frequency.

Most popular intervention types in "Pennsylvania Oncology Hematology Associates" are "Drug" (41 trials), "Biological" (4 trials), "Other" (3 trials), "Genetic" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "leucovorin calcium" (4 trials), "oxaliplatin" (4 trials), "Doxorubicin" (3 trials), "Placebo" (3 trials) and "bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Pennsylvania Oncology Hematology Associates" are 38 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Pennsylvania Oncology Hematology Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in Pennsylvania Oncology Hematology Associates, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Pennsylvania Oncology Hematology Associates, 5 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".